S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.34
$7.67
52-Week Range
N/A
Volume
32,246 shs
Average Volume
763,526 shs
Market Capitalization
$291.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CBIO stock logo

About Catalyst Biosciences Stock (NASDAQ:CBIO)

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CBIO Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CBIO - Catalyst Biosciences, Inc.
5 Cheap Healthcare Stocks to Buy in 2023
12 Cheap Healthcare Stocks to Buy in 2023
Catalyst Biosciences Provides Corporate Update
Catalyst/Millburn Hedge Strategy I
5 Stocks with the Lowest PE Ratio
See More Headlines
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/17/2023
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
7
Year Founded
2003

Profitability

Net Income
$-8,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
($0.78) per share

Miscellaneous

Free Float
36,869,000
Market Cap
$291.29 million
Optionable
Optionable
Beta
1.05

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Nassim Usman Ph.D. (Age 63)
    President, CEO & Director
    Comp: $1.75M
  • Ms. Seline E. Miller CPA (Age 54)
    Senior VP of Finance, Interim Chief Financial & Principal Accounting Officer
    Comp: $707.55k
  • Ms. Ana Kapor
    Senior Director of Investor Relations & Corporate Communications

CBIO Stock Analysis - Frequently Asked Questions

When is Catalyst Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CBIO earnings forecast
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07).

When did Catalyst Biosciences' stock split?

Catalyst Biosciences shares reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

This page (NASDAQ:CBIO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners